Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 166 of 5804
-
New combo pill aims to shrink spleens and ease symptoms in bone marrow cancer
Disease control OngoingThis is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase…
Phase: PHASE3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Should kidney cancer patients have surgery alongside immunotherapy? a major trial aims to find out
Disease control Recruiting nowThis phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastat…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:09 UTC
-
Promising combo targets tough blood cancer before transplant
Disease control OngoingThis is a multicenter, open-label, non-randomized, phase II clinical trial conducted in Canada. The purpose of the study is to determine the remission rate of acalabrutinib in combination with R-CHOP in patients with previously untreated mantle cell lymphoma prior to autologous s…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can CAR-T cells free HIV patients from daily medication?
Disease control Recruiting nowThis is a limited-center, open-label dose escalating phase I/IIa study of autologous T cells expressing LVgp120duoCAR molecules in people with HIV infection. It will follow a 3+3 design. Dose escalation decisions will be made when a minimum of three participants have completed th…
Phase: PHASE1, PHASE2 • Sponsor: Steven Deeks • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Triple-drug inhaler aims to tame severe asthma in teens and adults
Disease control CompletedThis is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Frozen ovary tissue reimplanted to reverse infertility after cancer
Disease control Recruiting nowChemotherapy and radiation for cancer and other conditions can cause infertility. Several centers around the world are cryopreserving ovarian tissue from these patients though an experimental protocol, including the Fertility Preservation Program in Pittsburgh (protocol PRO080504…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Can a drug free myelofibrosis patients from frequent blood transfusions?
Disease control OngoingThe purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red bl…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Immunotherapy plus chemo shows promise in tough lung cancer
Disease control CompletedPatients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the study doctor, which is either standard chemotherapy …
Phase: PHASE3 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can more intensive therapy replace anxiety meds for kids?
Disease control OngoingPediatric onset anxiety disorders (generalized anxiety, social anxiety, separation anxiety) are highly prevalent, and if untreated, are impairing into adolescence and adulthood. In the largest comparative efficacy study remission occurred in about 65% of children and adolescents …
Phase: PHASE3 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Double immunotherapy attack shows promise for tough lung cancer
Disease control OngoingThis is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Phase: PHASE2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to fight returning head and neck cancer
Disease control OngoingTo Study Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.
Phase: PHASE1, PHASE2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Sound waves zapping liver tumors: no knife needed?
Disease control OngoingThis trial is a single arm, non-randomized prospective trial. The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System for the treatment of primary or metastatic tumors located in the liver. The co-primary safety and efficacy endpoints must be …
Phase: NA • Sponsor: HistoSonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a three-drug cocktail outsmart resistant prostate cancer?
Disease control OngoingThis phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). ZEN-3694 blocks the expression of the MYC gene to prevent cellular gro…
Phase: PHASE2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug cocktail aims to stop bile duct cancer from returning after surgery
Disease control OngoingA randomized controlled, multicenter, open, seamless phase II-III clinical trial is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative recurrence-free survival. In this study, we aim …
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:52 UTC
-
Promising new combo tackles melanoma brain metastases in phase 2 trial
Disease control Recruiting nowThis phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells …
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:43 UTC
-
New cocktail of drugs and radiation takes on tough lung cancer
Disease control OngoingThis phase I/II trials investigates the side effects of olaparib and durvalumab and how well it works in combination with carboplatin, etoposide, and/or radiation therapy in treating patients with extensive stage-small cell lung cancer (ES-SCLC) who have not received treatment fo…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy aims to beat back tough lymphoma
Disease control Recruiting nowThis phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). T cells a…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug shows promise for rare HER2-Mutated cancers
Disease control OngoingThis is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are pati…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo could cut malaria risks in pregnancy
Prevention CompletedThis trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) + dihydroartemisin-piperaquine (DP) will significantly reduce the risk of adverse birth outcomes compared to IPTp with SP alone or DP alone. This double-…
Phase: PHASE3 • Sponsor: Grant Dorsey, M.D, Ph.D. • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC
-
Immunotherapy shows promise for tough brain cancers
Disease control OngoingThis phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden). Cancer is caused by changes (mutations) to genes that control the w…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC